BridgeBio Oncology Therapeutics (BBOT) risk factors, FY2025 10-K

What changed since the prior 10-K

New

• NewRisks Related to BBOT’s Financial Position and Need for Additional Capital

  BBOT has a limited operating history, has not completed any clinical trials, has no products approved for commercial sale and has not generated any revenue, which may make it difficult for investors to evaluate BBOT’s current business and likelihood of success and viability

  BBOT has a limited operating history starting in May 2024, has completed no clinical trials, and generated zero revenue from products.

• NewRisks Related to BBOT’s Financial Position and Need for Additional Capital

  BBOT has incurred significant net losses in each period since its inception, and expects to continue to incur significant net losses for the foreseeable future

  BBOT reported net losses of $134.0 million for 2025 and $74.3 million for 2024, with an accumulated deficit of $356.6 million.

• NewRisks Related to BBOT’s Financial Position and Need for Additional Capital

  BBOT’s ability to generate revenue and achieve profitability depends significantly on its ability to achieve its objectives relating to the discovery, development and commercialization of its product candidates

  BBOT depends entirely on the success of its precision oncology drug discovery approach and clinical trials for candidates like BBO-8520, BBO-10203, and BBO-11818.

• NewRisks Related to BBOT’s Financial Position and Need for Additional Capital

  attracting, hiring and retaining qualified personnel

  Failure to achieve profitability would impair BBOT's research efforts and force it to delay or reduce its drug development programs.

• NewRisks Related to BBOT’s Financial Position and Need for Additional Capital

  BBOT estimates that its existing cash, cash equivalents and short-term marketable securities as of the date of this report will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into early 2028

  BBOT estimates its existing cash and marketable securities will fund operations only into early 2028.

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  BBOT’s ability to address any potential delays resulting from factors related to public health emergencies, natural disasters or geopolitical events

  Uncontrolled factors like public health emergencies or geopolitical events could delay preclinical and clinical development and harm BBOT's business.

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  BBOT’s preclinical studies and clinical trials may fail to adequately demonstrate the safety and efficacy of any of its product candidates, which would prevent or delay development, regulatory approval and commercialization

  BBOT's preclinical studies and clinical trials may fail to demonstrate safety and efficacy for FDA or EMA approval.

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  regulators revising the requirements for approving BBOT’s product candidates

  Revised regulatory requirements could force BBOT to conduct additional costly clinical trials or cause drug withdrawals.

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  BBOT’s discovery and development activities are focused on precision oncology to treat RAS-dependent cancers, which is a rapidly evolving area of science, and the approach BBOT is taking to discover and develop drugs may never lead to approved or marketable products

  BBOT focuses on precision oncology for RAS-dependent cancers, an emerging and evolving scientific field with limited preliminary evidence.

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  Any delays in the commencement or completion, or any termination or suspension, of BBOT’s current, planned or future clinical trials could result in increased costs to BBOT, delay or limit BBOT’s ability to generate revenue and adversely affect BBOT’s commercial prospects

  Delays or suspensions in clinical trials required by the FDA or EMA would increase costs and delay potential revenue.

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  Further, if BBOT is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, BBOT’s development plans may be impacted

  Financial relationships between BBOT and clinical trial investigators could create conflicts of interest that jeopardize FDA data integrity.

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of BBOT’s clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities

  Preclinical and early clinical trial results may not successfully predict the outcomes of later-stage clinical trials.

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  In addition to BBO-8520, BBO-10203 and BBO-11818, BBOT’s prospects depend in part upon discovering, developing and commercializing additional product candidates from BBOT’s discovery programs, which may fail in development or suffer delays that adversely affect their commercial viability

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  addressing any delays resulting from factors related to public health emergencies, natural disasters or geopolitical events

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  BBOT’s approach to the discovery and development of product candidates is unproven, and BBOT may not be successful in its efforts to use and expand its approach to build a pipeline of product candidates with commercial value

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  BBOT may not be able to submit INDs, CTAs or comparable applications to commence clinical trials on the timelines BBOT expects, and even if BBOT is able to, the FDA, EMA or any comparable foreign regulatory authority may not permit BBOT to proceed

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  Interim, preliminary and topline data from BBOT’s preclinical studies and clinical trials that BBOT announces or publishes from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  If BBOT experiences delays or difficulties in the enrollment or maintenance of patients in clinical trials, BBOT’s regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  the possible termination or non-renewal of the agreement by the third party at a time that is costly or inconvenient for BBOT

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  BBOT faces substantial competition which may result in others discovering, developing or commercializing products before or more successfully than BBOT does

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  For BBO-11818, there are no pan-KRAS inhibitors approved by the FDA for the treatment of KRASG12X mutant lung, colorectal, or pancreatic cancers

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  BBOT’s product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  the approval of other new therapies for the same indications

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  The market opportunities for any product candidates BBOT develops, if approved, may be limited to certain smaller patient subsets and may be smaller than BBOT estimates them to be

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  Any product candidates BBOT develops may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  BBOT’s business entails a significant risk of product liability and if BBOT is unable to obtain sufficient insurance coverage such inability could have an adverse effect on BBOT’s business and financial condition

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  Certain of BBOT’s product candidates are novel, complex and difficult to manufacture. BBOT could experience manufacturing problems that result in delays in BBOT’s development or commercialization or otherwise harm BBOT’s business

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  disasters, disruption in utility services, human error or disruptions in the operations of BBOT’s suppliers, including historical disruptions, which could reoccur in connection with any future global pandemic or health emergency

• NewRisks Related to BBOT’s Product Development, Regulatory Approval and Commercialization

  Certain of BBOT’s product candidates are under development for the treatment of patient populations with significant comorbidities that may result in deaths or serious adverse or unacceptable side effects and require BBOT to abandon or limit its clinical development activities

• NewRisks Related to Regulatory Approval and Other Legal Compliance Matters

  BBOT may be unable to obtain U.S. or foreign regulatory approval and, as a result, may be unable to commercialize its product candidates

• NewRisks Related to Regulatory Approval and Other Legal Compliance Matters

  BBOT plans to develop certain of its current product candidates and potentially future product candidates in combination with other therapies, which would expose BBOT to additional risks

• NewRisks Related to Regulatory Approval and Other Legal Compliance Matters

  BBOT has conducted and intends to continue conducting certain of its clinical trials globally. However, the FDA and other foreign equivalents may not accept data from such trials, in which case BBOT’s development plans may be delayed, which could materially harm BBOT’s business

• NewRisks Related to Regulatory Approval and Other Legal Compliance Matters

  Obtaining and maintaining regulatory approval of BBOT’s product candidates in one jurisdiction does not mean that BBOT will be successful in obtaining regulatory approval of its product candidates in other jurisdictions

• NewRisks Related to Regulatory Approval and Other Legal Compliance Matters

  Even if BBOT’s product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight

• NewRisks Related to Regulatory Approval and Other Legal Compliance Matters

  requirements to conduct additional post-market clinical trials to assess the safety of the product

• NewRisks Related to Regulatory Approval and Other Legal Compliance Matters

  The FDA, EMA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses

• NewRisks Related to Regulatory Approval and Other Legal Compliance Matters

  BBOT may not be able to obtain orphan drug designation or obtain or maintain orphan drug exclusivity for its product candidates and, even if BBOT does, that exclusivity may not prevent the FDA, EMA or other comparable foreign regulatory authorities, from approving competing products

• NewRisks Related to Regulatory Approval and Other Legal Compliance Matters

  Current and future legislative and regulatory reform measures and cost containment initiatives may increase the difficulty and cost for BBOT to obtain adequate reimbursement for its product candidates and may adversely affect the prices we may set

• NewRisks Related to Regulatory Approval and Other Legal Compliance Matters

  BBOT’s employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements

• NewRisks Related to Regulatory Approval and Other Legal Compliance Matters

  If BBOT fails to comply with applicable environmental, health and safety laws and regulations, BBOT could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of BBOT’s business

• NewRisks Related to BBOT’s Business

  BBOT’s success is highly dependent on BBOT’s ability to attract, hire and retain highly skilled executive officers and employees, and BBOT may experience difficulties in managing the future growth of BBOT’s organization

• NewRisks Related to BBOT’s Business

  improving BBOT’s operational, financial and management controls, reporting systems and procedures

• NewRisks Related to BBOT’s Business

  BBOT’s reliance on a limited number of employees who provide various administrative, research and development, and other services across BBOT’s organization presents operational challenges that may adversely affect BBOT’s business

• NewRisks Related to BBOT’s Business

  BBOT’s operations are vulnerable to interruption by flood, fire, earthquakes, power loss, telecommunications failure, terrorist activity, pandemics and other events beyond BBOT’s control, which could harm BBOT’s business

• NewRisks Related to BBOT’s Business

  A variety of risks associated with marketing BBOT’s product candidates internationally could materially adversely affect BBOT’s business

• NewRisks Related to BBOT’s Business

  Changes in tax law could adversely affect BBOT’s business and financial condition

• NewRisks Related to BBOT’s Business

  BBOT’s ability to utilize its net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited

• NewRisks Related to BBOT’s Business

  If BBOT engages in future acquisitions or strategic partnerships, this may increase BBOT’s capital requirements, dilute BBOT’s stockholders, cause BBOT to incur debt or assume contingent liabilities, and subject BBOT to other risks

• NewRisks Related to BBOT’s Business

  BBOT’s inability to generate revenue from acquired technology and/or products sufficient to meet BBOT’s objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs

• NewRisks Related to BBOT’s Business

  Adverse events in the field of oncology or the biopharmaceutical industry could damage public perception of BBOT’s current or future product candidates and negatively affect BBOT’s business

• NewRisks Related to BBOT’s Intellectual Property

  Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require BBOT to cease using the related technology or to attempt to license rights from the prevailing party

• NewRisks Related to BBOT’s Intellectual Property

  Patent terms may not protect BBOT’s competitive position for an adequate amount of time

• NewRisks Related to BBOT’s Intellectual Property

  Changes to patent laws in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing BBOT’s ability to protect its products

• NewRisks Related to BBOT’s Intellectual Property

  BBOT may become involved in lawsuits to protect or enforce its patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful

• NewRisks Related to BBOT’s Intellectual Property

  unenforceability are unpredictable. With respect to validity, for example, even if BBOT is successful in obtaining patents or in-licensing patents, BBOT cannot be certain that there is no invalidating prior art of which the patent examiner and BBOT or its future licensing partners were unaware during prosecution

• NewRisks Related to BBOT’s Intellectual Property

  Third parties may allege that BBOT is infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on BBOT’s business

• NewRisks Related to BBOT’s Intellectual Property

  If BBOT is unable to obtain licenses from third parties on commercially reasonable terms, BBOT’s business could be adversely affected

• NewRisks Related to BBOT’s Intellectual Property

  If BBOT fails to comply with its obligations in any future intellectual property licenses with third parties that BBOT may enter into, or otherwise experiences disruptions to its business relationships with future licensors, BBOT could lose intellectual property rights that are important to BBOT’s business

• NewRisks Related to BBOT’s Intellectual Property

  If BBOT does not prevail in such disputes, BBOT may lose any or all of its rights under such license agreements

• NewRisks Related to BBOT’s Intellectual Property

  Third parties may attempt to develop and commercialize competitive products in foreign countries where BBOT does not have any patent protection and/or where legal recourse may be limited. This may have a significant commercial impact on BBOT’s foreign business operations

• NewRisks Related to BBOT’s Intellectual Property

  Intellectual property rights do not necessarily address all potential threats

• NewRisks Related to BBOT’s Intellectual Property

  BBOT may be subject to claims challenging the inventorship or ownership of its patents and other intellectual property

• NewRisks Related to BBOT’s Intellectual Property

  BBOT may not identify relevant third-party patents or pending patent applications or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect BBOT’s ability to develop and market its product candidates

• NewRisks Related to BBOT’s Intellectual Property

  If BBOT is unable to protect the confidentiality of its trade secrets and other proprietary information, BBOT’s business and competitive position would be adversely affected

• NewRisks Related to BBOT’s Intellectual Property

  If BBOT’s trademarks and trade names are not adequately protected, BBOT may not be able to build name recognition in its markets of interest and BBOT’s business may be adversely affected

• NewRisks Related to BBOT’s Intellectual Property

  If BBOT does not obtain patent term extension in the U.S. under the Hatch-Waxman Act and in foreign countries under similar legislation, which if granted could extend the term of BBOT’s marketing exclusivity for any product candidates BBOT may develop, BBOT’s business may be materially and adversely affected

• NewRisks Related to BBOT’s Dependence on Third Parties

  BBOT relies on third parties to conduct its preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies

• NewRisks Related to BBOT’s Dependence on Third Parties

  BBOT’s manufacturing process needs to comply with FDA regulations relating to the quality and reliability of such processes. Any failure to comply with relevant regulations could result in delays in or termination of BBOT’s clinical programs and suspension or withdrawal of any regulatory approvals

• NewRisks Related to BBOT’s Dependence on Third Parties

  If BBOT’s third-party manufacturers use hazardous materials in a manner that causes injury or violates applicable law, BBOT may be liable for damages

• NewRisks Related to BBOT’s Dependence on Third Parties

  If BBOT decides to establish collaborations but is not able to establish those collaborations on commercially reasonable terms, BBOT may have to alter its development and commercialization plans

• NewRisks Related to BBOT’s Dependence on Third Parties

  BBOT may enter into collaborations with third parties for the development and commercialization of product candidates. If those collaborations are not successful, BBOT may not be able to capitalize on the market potential of these product candidates

• NewRisks Related to BBOT’s Dependence on Third Parties

  a collaborator’s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings

• NewRisks Related to Operating as a Public Company

  There may not be an active trading market for our common stock, which may make it difficult to sell shares of our common stock

• NewRisks Related to Operating as a Public Company

  The market price of our common stock may be volatile, and investors could lose all or part of their investment

• NewRisks Related to Operating as a Public Company

  If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding BBOT, BBOT’s business or BBOT’s market, the Company’s stock price and trading volume could decline

• NewRisks Related to Operating as a Public Company

  BBOT’s operating results may fluctuate significantly, which makes BBOT’s future operating results difficult to predict and could cause BBOT’s operating results to fall below expectations or guidance

• NewRisks Related to Operating as a Public Company

  the changing, volatile and instable global economic and political environment

• NewRisks Related to Operating as a Public Company

  Several of our principal stockholders own a significant percentage of our Common Stock and can exert significant control over matters subject to stockholder approval

• NewRisks Related to Operating as a Public Company

  Future sales, or the perception of future sales, by the Company or its stockholders in the public market could cause the market price for the Company’s securities to decline

• NewRisks Related to Operating as a Public Company

  Raising additional capital may cause dilution to the Company’s existing stockholders, restrict BBOT’s operations or require BBOT to relinquish rights to its technologies or product candidates

• NewRisks Related to Operating as a Public Company

  BBOT has increased costs as a result of operating as a public company, and BBOT’s management devotes substantial time to related compliance initiatives

• NewRisks Related to Operating as a Public Company

  Although BBOT has remediated this material weakness and has not identified any material weaknesses in connection with the finalization of its consolidated financial statements as of and for the year ended December 31, 2025, BBOT cannot provide assurance that it will not identify other material weaknesses in the future

• NewRisks Related to Operating as a Public Company

  BBOT’s projections of both the number of people who have the diseases its product candidates are targeting, as well as the subset of people with such disease who have the potential to benefit from treatment with any of BBOT’s product candidates, are based on estimates

• NewRisks Related to Operating as a Public Company

  BBOT’s disclosure controls and procedures may not prevent or detect all errors or acts of fraud

• NewRisks Related to Operating as a Public Company

  BBOT does not intend to pay dividends on BBOT common stock so any returns will be limited to the value of BBOT’s stock

• NewRisks Related to Operating as a Public Company

  Anti-takeover provisions in BBOT’s Charter and Bylaws and Delaware law might discourage, delay or prevent a change in control of BBOT or changes in BBOT’s management and, therefore, depress the market price of Common Stock

• NewRisks Related to Operating as a Public Company

  the authority of the BBOT Board to issue preferred stock on terms determined by the Company’s board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock

• NewRisks Related to Operating as a Public Company

  We face risks associated with tariffs and other trade restrictions, which may have a material adverse impact on our results of operations and financial condition

• NewRisks Related to Operating as a Public Company

  Additionally, Helix was a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of financial statements

Dropped

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  Your only opportunity to effect your investment decision regarding a potential business combination may be limited to the exercise of your right to redeem your shares from us for cash

  Investor redemption rights limitation during a potential business combination.

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  As of December 31, 2024, our initial shareholders owned 4,600,000 founder shares, which represented 20% of our issued and outstanding ordinary shares

  Initial shareholders owning 4,600,000 founder shares representing 20% of ordinary shares.

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  The ability of our public shareholders to redeem their shares for cash may make our financial condition unattractive to potential business combination targets, which may make it difficult for us to enter into a business combination with a target

  Public shareholder redemption rights making financial conditions unattractive to targets.

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  The ability of our public shareholders to exercise redemption rights with respect to a large number of our shares could increase the probability that our initial business combination would be unsuccessful and that you would have to wait for liquidation in order to redeem your shares

  Large-scale public shareholder redemption rights increasing business combination failure rates.

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  We may not be able to complete our initial business combination within the completion window, in which case we would redeem our Public Shares

  Risk of failing to complete the initial business combination within the completion window.

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  We may decide not to extend the term we have to consummate our initial business combination, in which case we would redeem our Public Shares

  Decision not to extend the term to consummate the initial business combination.

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  If a shareholder fails to receive notice of our offer to redeem our Public Shares in connection with our initial business combination, or fails to comply with the procedures for submitting or tendering its shares, such shares may not be redeemed

  Shareholder failure to receive notice of redemption offers or comply with procedures.

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  You will not be entitled to protections normally afforded to investors of other blank check companies subject to Rule 419 of the Securities Act

  Inapplicability of Rule 419 protections for blank check companies.

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  If third parties bring claims against us, the proceeds held in the Trust Account could be reduced and the per-share redemption amount received by shareholders may be less than $10.00 per share

  Third-party claims reducing trust account proceeds and per-share redemption amounts.

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  Our directors may decide not to enforce the indemnification obligations of our Sponsor, resulting in a reduction in the amount of funds in the Trust Account available for distribution to our public shareholders

  Directors deciding not to enforce sponsor indemnification obligations.

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  We may not have sufficient funds to satisfy indemnification claims of our Sponsor, Cormorant, directors and officers

  Insufficient funds to satisfy indemnification claims of sponsors and officers.

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our business, including our ability to negotiate and complete our initial business combination, and results of operations, including the BBOT Business Combination

  Changes in laws or regulations adversely affecting business and combination completion.

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  If we are unable to consummate our initial business combination within the completion window, our public shareholders may be forced to wait beyond the end of the completion window before redemption from our Trust Account

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  Our shareholders may be held liable for claims by third parties against us to the extent of distributions received by them upon redemption of their shares

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  We may not hold an annual general meeting until after the consummation of our initial business combination, which could delay the opportunity for our shareholders to appoint directors

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  Because we are neither limited to evaluating a target business in a particular industry sector nor have we selected any target businesses with which to pursue our initial business combination, you will be unable to ascertain the merits or risks of any particular target business’s operations

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  We may seek business combination opportunities in industries or sectors that may be outside of our management’s areas of expertise

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  Unlike some other similarly structured special purpose acquisition companies, our initial shareholders will receive additional Class A ordinary shares if we issue certain shares to consummate an initial business combination

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  We may issue our shares to investors in connection with our initial business combination at a price which is less than the prevailing market price of our shares at that time

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  We may engage in a business combination with one or more target businesses that have relationships with entities that may be affiliated with our Sponsor, officers, directors or existing holders which may raise potential conflicts of interest

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  We may issue notes or other debt securities, or otherwise incur substantial debt, to complete a business combination, which may adversely affect our leverage and financial condition and thus negatively impact the value of our shareholders’ investment in us

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  We may attempt to simultaneously complete business combinations with multiple prospective targets, which may hinder our ability to complete our initial business combination and give rise to increased costs and risks that could negatively impact our operations and profitability

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  We may attempt to complete our initial business combination with a private company about which little information is available, which may result in a business combination with a company that is not as profitable as we suspected, if at all

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  We do not have a specified maximum redemption threshold. The absence of such a redemption threshold may make it possible for us to complete our initial business combination with which a substantial majority of our shareholders do not agree

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  We may be unable to obtain additional financing to complete our initial business combination or to fund the operations and growth of a target business, which could compel us to restructure or abandon a particular business combination

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  Our initial shareholders control a substantial interest in us and thus may exert a substantial influence on actions requiring a shareholder vote, potentially in a manner that you do not support

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  Because we must furnish our shareholders with target business financial statements, we may lose the ability to complete an otherwise advantageous initial business combination with some prospective target businesses

• DroppedRisks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  Compliance obligations under the Sarbanes-Oxley Act may make it more difficult for us to effectuate our initial business combination, require substantial financial and management resources, and increase the time and costs of completing an initial business combination

• DroppedRisks Relating to the Post-Business Combination Company

  Our management may not be able to maintain control of a target business after our initial business combination. We cannot provide assurance that, upon loss of control of a target business, new management will possess the skills, qualifications or abilities necessary to profitably operate such business

• DroppedRisks Relating to the Post-Business Combination Company

  We may reincorporate in or transfer by way of continuation to another jurisdiction in connection with our initial business combination, and the laws of such jurisdiction may govern some or all of our future material agreements and we may not be able to enforce our legal rights

• DroppedRisks Relating to the Post-Business Combination Company

  We may reincorporate in another jurisdiction, which may result in taxes imposed on our shareholders

• DroppedRisks Relating to the Post-Business Combination Company

  The officers and directors of an acquisition candidate may resign upon completion of our initial business combination. The loss of a business combination target’s key personnel could negatively impact the operations and profitability of our post-combination business

• DroppedRisks Relating to the Post-Business Combination Company

  We may seek business combination opportunities with a high degree of complexity that require significant operational improvements, which could delay or prevent us from achieving our desired results

• DroppedRisks Relating to the Post-Business Combination Company

  If our management following our initial business combination is unfamiliar with U.S. securities laws, they may have to expend time and resources becoming familiar with such laws, which could lead to various regulatory issues

• DroppedRisks Relating to Acquiring and Operating a Business in Foreign Countries

  If we effect our initial business combination with a company located outside of the United States, we would be subject to a variety of additional risks that may adversely affect us

• DroppedRisks Relating to Acquiring and Operating a Business in Foreign Countries

  Exchange rate fluctuations and currency policies may cause a target business’ ability to succeed in the international markets to be diminished

• DroppedRisks Relating to Acquiring and Operating a Business in Foreign Countries

  If we acquire a non-U.S. target, our results of operations may be negatively impacted because of the costs and difficulties inherent in managing cross-border business operations

• DroppedRisks Relating to Acquiring and Operating a Business in Foreign Countries

  If social unrest, acts of terrorism, regime changes, changes in laws and regulations, political upheaval or policy changes or enactments occur in a country in which we may operate after we effect our initial business combination, it may result in a negative impact on our business

• DroppedRisks Relating to Acquiring and Operating a Business in Foreign Countries

  Many countries have difficult and unpredictable legal systems and underdeveloped laws and regulations that are unclear and subject to corruption and inexperience, which may adversely impact our results of operations and financial condition

• DroppedRisks Relating to Acquiring and Operating a Business in Foreign Countries

  Because foreign law could govern almost all of our material agreements, we may not be able to enforce our rights within such jurisdiction or elsewhere, which could result in a significant loss of business, business opportunities or capital

• DroppedRisks Relating to Our Sponsor and Management Team

  We are dependent upon our officers and directors and their loss, or a reduction in the amount of time they can dedicate to our initial business combination, could adversely affect our ability to operate

• DroppedRisks Relating to Our Sponsor and Management Team

  Our officers and directors will allocate their time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs. This conflict of interest could have a negative impact on our ability to complete our initial business combination

• DroppedRisks Relating to Our Sponsor and Management Team

  Our officers, directors, security holders and their respective affiliates may have competitive pecuniary interests that conflict with our interests

• DroppedRisks Relating to Our Sponsor and Management Team

  Members of our management team and affiliated companies may have been, and may in the future be, involved in civil disputes or governmental investigations unrelated to our business

• DroppedRisks Relating to Our Sponsor and Management Team

  Our Letter Agreement with our Sponsor, officers, directors and advisors may be amended without shareholder approval

• DroppedRisks Relating to our Securities

  You will not have any rights or interests in funds from the Trust Account, except under certain limited circumstances. Therefore, to liquidate your investment, you may be forced to sell your Public Shares, potentially at a loss

• DroppedRisks Relating to our Securities

  If we are unable to consummate our initial business combination within the completion window, our public shareholders may be forced to wait beyond such completion window before redemption from our Trust Account

• DroppedRisks Relating to our Securities

  Nasdaq may delist our Class A ordinary shares from trading on its exchange, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions

• DroppedRisks Relating to our Securities

  The grant of registration rights to our initial shareholders and holders of our Private Placement Shares may make it more difficult to complete our initial business combination, and the future exercise of such rights may adversely affect the market price of our Class A ordinary shares

• DroppedRisks Relating to our Securities

  Our initial shareholders have paid an aggregate of $25,000, or approximately $0.009 per founder share and, accordingly, you will experience immediate and substantial dilution from the purchase of our Class A ordinary shares

• DroppedRisks Relating to our Securities

  Implied value per share upon consummation of initial business combination(2) $ 7.58

• DroppedRisks Relating to our Securities

  (2) All founder shares would automatically convert into Class A ordinary shares upon completion of our initial business combination or earlier at the option of the holder

• DroppedRisks Relating to our Securities

  We are a blank check company with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective

• DroppedRisks Relating to our Securities

  Past performance by our management team, our advisors and their respective affiliates, including investments and transactions in which they have participated and businesses with which they have been associated, may not be indicative of future performance of an investment in the Company

• DroppedRisks Relating to our Securities

  The 1% U.S. federal excise tax on stock buybacks could be imposed on redemptions of our stock if we were to become a “covered corporation” in the future

• DroppedRisks Relating to our Securities

  An investment in our securities may result in uncertain U.S. federal income tax consequences

• DroppedRisks Relating to our Securities

  After our initial business combination, it is possible that a majority of our directors and officers will live outside the United States and all of our assets will be located outside the United States; therefore, investors may not be able to enforce federal securities laws or their other legal rights

• DroppedRisks Relating to our Securities

  Because we are incorporated under the laws of the Cayman Islands, you may face difficulties in protecting your interests, and your ability to protect your rights through the U.S. Federal courts may be limited

• DroppedRisks Relating to our Securities

  Provisions in our Articles may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future for our Class A ordinary shares and could entrench management

• DroppedRisks Relating to our Securities

  Cyber incidents or attacks directed at us could result in information theft, data corruption, operational disruption and/or financial loss

• DroppedRisks Relating to our Securities

  Our Articles provide that the courts of the Cayman Islands will be the exclusive forums for certain disputes between us and our shareholders, which could limit our shareholders’ ability to obtain a favorable judicial forum for complaints against us or our directors, officers or employees

• DroppedRisks Relating to our Securities

  Changes in the market for directors and officers liability insurance could make it more difficult and more expensive for us to negotiate and complete an initial business combination

• DroppedRisks Relating to our Securities

  Recent increases in inflation in the United States and elsewhere could make it more difficult for us to complete our initial business combination

• DroppedRisks Relating to our Securities

  We are subject to changing law and regulations regarding regulatory matters, corporate governance and public disclosure that have increased both our costs and the risk of non-compliance

• DroppedRisks Relating to our Securities

  We employ a mail forwarding service, which may delay or disrupt our ability to receive mail in a timely manner

All 90 risk factors

Headings as the filing states them, in filing order.

Other BridgeBio Oncology Therapeutics 10-Ks

• FY2024 10-K risk factors

  65 risks

  This company is a special purpose acquisition company (SPAC) formed to complete an initial business combination, specifically the BBOT Business Combination. Risks are dominated by shareholder redemption mechanics, trust account protections, and potential target qualification issues. Operations and investments depend entirely on successfully acquiring a target business within the allotted completion window.

  Filed Mar 11, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.